title: Genotype-phenotype analysis of CYP2C19 in healthy saudi individuals and its potential clinical implication in drug therapy.
abstract: CYP2C19 is a cytochrome P450 enzyme, which is involved in the metabolism of some clinically important medications and is encoded by a highly polymorphic gene. There is no available data on the distribution of the CYP2C19 *4 and *17 mutant alleles in the Saudi Arabian population. The aim of the study was to determine different CYP2C19 mutant allele (*2, *4 and *17) frequencies in healthy Saudi subjects and to determine genotype frequencies for these mutations. The CYP2C19 genotypes were then classified into phenotypes.
  
  
  RESULTS
  In 201 adults of Saudi ethnicity, the allele frequencies were CYP2C19*1 (62.9%), *17 (25.7%), *2 (11.2%) and *4 (0.2%). The most prevalent genotype combinations were CYP2C19 *1/*1 (40.3%) and *1/*17 (30.4%). The distribution of CYP2C19 phenotypes was divided into extensive metabolizers (EM) 77.6%, intermediate metabolizers (IM) 14.9%, ultra-rapid metabolizers (UM) 7% and poor metabolizers (PM) 0.4%. This finding has important clinical implications for the use of CYP2C19 metabolized medications in the Saudi population and further studies are needed.
authors.affiliation: 1. King Fahad Medical City, P.O. Box 59046, Riyadh 11525, Kingdom of Saudi Arabia.
authors.forename: Leena H
authors.initials: LH
authors.lastname: Saeed
authors.forename: Ahmed Y
authors.initials: AY
authors.lastname: Mayet
mesh_terms: D001189:Aryl Hydrocarbon Hydroxylases / Q000235:genetics*; D065731:Cytochrome P-450 CYP2C19; D003577:Cytochrome P-450 Enzyme System / Q000235:genetics; D005838:Genotype; D006801:Humans; D010641:Phenotype; D011110:Polymorphism, Genetic / Q000235:genetics; D012529:Saudi Arabia
chemical_list: D003577:Cytochrome P-450 Enzyme System; D001189:Aryl Hydrocarbon Hydroxylases; C045793:CYP2C19 protein, human; D065731:Cytochrome P-450 CYP2C19
keywords: CYP2C19; cytochrome P450; genotype; phenotype; polymorphism
references.citation: J Clin Pharm Ther. 2010 Dec;35(6):697-703
references.pmid: 21054462
references.citation: Clin Pharmacol Ther. 2006 Jan;79(1):103-13
references.pmid: 16413245
references.citation: Aliment Pharmacol Ther. 2003 Jan;17(2):259-64
references.pmid: 12534411
references.citation: Aliment Pharmacol Ther. 2003 Apr 1;17(7):965-73
references.pmid: 12656699
references.citation: Pharmacogenomics. 2008 Sep;9(9):1251-9
references.pmid: 18781853
references.citation: Drug Metab Dispos. 2010 Jun;38(6):894-7
references.pmid: 20223877
references.citation: Mutat Res. 2008 Sep 26;644(1-2):31-7
references.pmid: 18644391
references.citation: Pharmacogenetics. 1997 Feb;7(1):59-64
references.pmid: 9110363
references.citation: Pharmacogenetics. 1999 Oct;9(5):539-49
references.pmid: 10591534
references.citation: Br J Clin Pharmacol. 2008 Mar;65(3):437-9
references.pmid: 18241287
references.citation: BMC Clin Pharmacol. 2007 Jul 11;7:6
references.pmid: 17623107
references.citation: Br J Clin Pharmacol. 2002 Jun;53(6):596-603
references.pmid: 12047484
references.citation: Clin Pharmacol Ther. 1999 Mar;65(3):275-82
references.pmid: 10096259
references.citation: Clin Pharmacol Ther. 2006 Jul;80(1):33-40
references.pmid: 16815315
references.citation: N Engl J Med. 2009 Jan 22;360(4):363-75
references.pmid: 19106083
references.citation: Fundam Clin Pharmacol. 2003 Feb;17(1):27-41
references.pmid: 12588628
references.citation: Xenobiotica. 1996 Nov;26(11):1155-66
references.pmid: 8948091
references.citation: Br J Clin Pharmacol. 1998 Apr;45(4):369-75
references.pmid: 9578184
references.citation: Pharmacogenomics. 2004 Mar;5(2):181-202
references.pmid: 15016609
references.citation: Pharmacol Res. 2004 Aug;50(2):195-200
references.pmid: 15177309
references.citation: Eur J Clin Pharmacol. 2003 Aug;59(4):303-12
references.pmid: 12879168
references.citation: Pharmacogenomics. 2007 Jul;8(7):703-12
references.pmid: 18240903
references.citation: J Thromb Haemost. 2009 Aug;7(8):1409-11
references.pmid: 19496924
references.citation: Circulation. 2010 Feb 2;121(4):512-8
references.pmid: 20083681
references.citation: Mol Biol Rep. 2011 Nov;38(8):5449-52
references.pmid: 21380557
references.citation: Clin Exp Pharmacol Physiol. 2007 Jan-Feb;34(1-2):102-5
references.pmid: 17201743
references.citation: Lancet. 2009 Jan 24;373(9660):309-17
references.pmid: 19108880
references.citation: Clin Pharmacol Ther. 2001 Nov;70(5):484-92
references.pmid: 11719736
references.citation: Clin Pharmacol Ther. 1999 Nov;66(5):528-34
references.pmid: 10579481
references.citation: Eur J Clin Pharmacol. 2006 Oct;62(10):877-80
references.pmid: 16912869
references.citation: Clin Pharmacol Ther. 1998 Oct;64(4):391-401
references.pmid: 9797796
references.citation: Br J Clin Pharmacol. 2001 Oct;52(4):349-55
references.pmid: 11678778
references.citation: J Am Coll Cardiol. 2008 May 20;51(20):1925-34
references.pmid: 18482659
references.citation: N Engl J Med. 2009 Jan 22;360(4):354-62
references.pmid: 19106084
references.citation: J Cardiol. 2011 Mar;57(2):194-201
references.pmid: 21168310
references.citation: Pharmacogenomics. 2008 Jun;9(6):691-702
references.pmid: 18518848
references.citation: Biol Pharm Bull. 2002 Jul;25(7):923-7
references.pmid: 12132671
references.citation: Clin Pharmacol Ther. 1999 Aug;66(2):185-92
references.pmid: 10460072
references.citation: Pharmacol Rev. 2006 Sep;58(3):521-90
references.pmid: 16968950
references.citation: Br J Clin Pharmacol. 1999 Sep;48(3):409-15
references.pmid: 10510154
references.citation: Pharmacogenetics. 1996 Dec;6(6):521-6
references.pmid: 9014201
references.citation: Eur J Clin Pharmacol. 2010 Dec;66(12):1199-205
references.pmid: 20665013
references.citation: Drug Metab Pharmacokinet. 2006 Aug;21(4):286-90
references.pmid: 16946555
references.citation: Pharmacogenomics. 2009 Jan;10(1):43-9
references.pmid: 19102714
references.citation: Eur J Clin Pharmacol. 2005 May;61(3):179-84
references.pmid: 15776277